Institutional members access full text with Ovid®

Share this article on:

In Vivo Endothelial Cell Density Decline in the Early Postoperative Phase After Descemet Membrane Endothelial Keratoplasty

Miron, Alina, PDeng*,†,‡; Bruinsma, Marieke, PhD*,†; Ham, Lisanne, PhD*,†,‡; Schaal, Sontje-Chiao, MD*; Baydoun, Lamis, MD*,†; Dapena, Isabel, MD, PhD*,†; Oellerich, Silke, PhD*; Melles, Gerrit R., J., MD, PhD*,†,‡

doi: 10.1097/ICO.0000000000001484
Clinical Science

Purpose: To evaluate endothelial cell density (ECD) in the first 6 months after Descemet membrane endothelial keratoplasty (DMEK) by eliminating method error as a confounding variable.

Methods: From 24 DMEK eyes operated for Fuchs endothelial corneal dystrophy, from which specular microscopy images could be taken at 1 day and 6 months postoperatively, ECD values were compared between these 2 time points.

Results: Using the 1-day ECD measurement as baseline, mean ECD decreased from 1913 (±326) cells/mm2 to 1524 (±393) cells/mm2 at 6 months, a decline of −18 (±19)%. With the 1-week ECD as baseline [1658 (±395) cells/mm2], the decline at 6 months was −6 (±19)% and when using preoperative ECD as baseline [2521 (±122) cells/mm2], the decline was −39 (±16)% at 6 months.

Conclusions: After DMEK, ECD shows an in vivo decline of 18% from 1 day to 6 months postoperatively, with a sharp 13% drop in the first week, and a slower decrease thereafter. The remaining difference of 20% from preoperative ECD values may be attributed to a measurement error in the eye bank with an overestimation of the graft's viable endothelial cell population and/or intraoperative trauma to the graft.

*Netherlands Institute for Innovative Ocular Surgery, Rotterdam, The Netherlands;

Melles Cornea Clinic Rotterdam, Rotterdam, The Netherlands; and

Amnitrans EyeBank Rotterdam, Rotterdam, The Netherlands.

Correspondence: Gerrit R. J. Melles, MD, PhD, Netherlands Institute for Innovative Ocular Surgery, Laan op Zuid 88, 3071AA Rotterdam, The Netherlands (e-mail: research@niios.com).

G. R. J. Melles is a consultant for DORC International/Dutch Ophthalmic USA and SurgiCube International. L. Baydoun and I. Dapena are consultants for DORC International/Dutch Ophthalmic USA. The other authors have no funding or conflicts of interest to disclose.

Received October 11, 2017

Received in revised form October 25, 2017

Accepted October 25, 2017

Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.